PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
42.50%
Net income growth 1.25-1.5x AGEN's 33.61%. Bruce Berkowitz would verify whether cost discipline or revenue gains drive the outperformance.
0.99%
Some D&A expansion while AGEN is negative at -2.57%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-10.02%
Negative yoy SBC while AGEN is 743.80%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
66.71%
Less working capital growth vs. AGEN's 168.94%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Lower AP growth vs. AGEN's 416.18%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-209.52%
Negative yoy usage while AGEN is 91.70%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
100.00%
Some yoy increase while AGEN is negative at -111.07%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
51.97%
Operating cash flow growth 1.25-1.5x AGEN's 46.24%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.02%
Negative yoy issuance while AGEN is 4.57%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.